Cost effectiveness results of Early KRAS testing in high risk patients that would have no access to well-timed KRAS testing if they develop metastatic disease.
收藏NIAID Data Ecosystem2026-03-08 收录
数据链接：
官方服务：
资源简介：
ICER of cetuximab+FOLFOX vs bevacizumab+FOLFOX is lower than that of cetuximab+FOLFOX vs FOLFOX due to the limited advantage of bevacizumab+FOLFOX on FOLFOX. Differential cost of cetuximab+FOLFOX vs bevacizumab+FOLFOX is minimal whereas efficacy favours cetuximab+FOLFOX on FOLFOX.
创建时间：
2014-01-20
